MedWatch

Novo Nordisk seeks extended approval for diabetes drug in the US

The US FDA will now decide whether to expand the label for Novo Nordisk's drug Ozempic to also include a higher dose of the drug.

Photo: Stine Tidsvilde

Danish pharmaceutical firm Novo Nordisk has submitted a label expansion application for its diabetes drug Ozempic to the US Food and Drug Administration (FDA), according to a company press release.

The application aims at an approval of Ozempic for the treatment of type II diabetes with a dose of 2.0 mg, building on top of the 0.5 mg and 1.0 mg which have already been approved.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs